Tolvaptan-induced remission of primary palmar hyperhidrosis in a patient with ADPKD: a serendipitous finding
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Nephrology"
DOI: 10.1007/s40620-021-00973-8
Abstract: A 37-year old man had suffered palmar hyperhidrosis since he was fifteen years old. In the last year, he has been treated with tolvaptan for autosomic polycystic kidney disease (ADPKD). The start of tolvaptan therapy… read more here.
Keywords: system; tolvaptan; palmar hyperhidrosis; remission ... See more keywords
Comparison of the Tolvaptan Versus Furosemide-Based Diuretic Regimes in Patients Hospitalized for Heart Failure with Hyponatremia (AQUA-AHF)
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Cardiac Failure"
DOI: 10.1016/j.cardfail.2018.07.260
Abstract: Introduction Hyponatremia is associated with worse longitudinal outcomes, and recently, poorer diuretic response in patients hospitalized for heart failure (HF). Whether tolvaptan monotherapy is a viable alternative to intravenous loop diuretics for decongestive therapy has… read more here.
Keywords: tolvaptan; hospitalized heart; patients hospitalized; furosemide based ... See more keywords
Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease.
Sign Up to like & getrecommendations! Published in 2019 at "Kidney international"
DOI: 10.1016/j.kint.2018.11.044
Abstract: In the TEMPO 3:4 Trial, treatment with tolvaptan, a vasopressin V2 receptor antagonist, slowed the increase in total kidney volume and decline in estimated glomerular filtration rate (eGFR) in autosomal dominant polycystic kidney disease (ADPKD).… read more here.
Keywords: copeptin; plasma; tolvaptan; treatment ... See more keywords
Tolvaptan reduces angiotensin II-induced experimental abdominal aortic aneurysm and dissection.
Sign Up to like & getrecommendations! Published in 2022 at "Vascular pharmacology"
DOI: 10.1016/j.vph.2022.106973
Abstract: Tolvaptan has been approved for the treatment of autosomal dominant polycystic kidney disease and heart failure. However, the role of tolvaptan in patients with abdominal aortic aneurysm (AAA) has not been examined. Human aortic smooth… read more here.
Keywords: tolvaptan; abdominal aortic; dissection; tolvaptan reduces ... See more keywords
Heart failure: No early benefits of adjunct therapy with tolvaptan for acute heart failure
Sign Up to like & getrecommendations! Published in 2017 at "Nature Reviews Cardiology"
DOI: 10.1038/nrcardio.2017.46
Abstract: of tolvaptan in patients with acute heart failure and volume overload. J. Am. Coll. Cardiol. 69, 1409–1419 (2017) | Felker, G. M. et al. Efficacy and safety of tolvaptan in patients hospitalized with acute heart… read more here.
Keywords: heart; tolvaptan; secret chf; heart failure ... See more keywords
Short-term effects of low-dose tolvaptan in acute decompensated heart failure patients with severe aortic stenosis: the LOHAS registry
Sign Up to like & getrecommendations! Published in 2020 at "European Heart Journal"
DOI: 10.1093/ehjci/ehaa946.1226
Abstract: Tolvaptan exerts potent diuretic effects in heart failure patients without hemodynamic instability. Nonetheless, its clinical efficacy for acute decompensated heart failure (ADHF) due to severe aortic stenosis (AS) remains unclear. This study aimed to evaluate… read more here.
Keywords: short term; heart; tolvaptan; heart failure ... See more keywords
MO040REAL-WORLD USE OF TOLVAPTAN AND ITS IMPACT ON EGFR IN A NORTH EAST UK COHORT
Sign Up to like & getrecommendations! Published in 2021 at "Nephrology Dialysis Transplantation"
DOI: 10.1093/ndt/gfab080.0012
Abstract: Autosomal dominant polycystic kidney disease (ADPKD) is a cause of progressive chronic kidney failure (CKD) and end stage kidney disease (ESKD). Tolvaptan has been shown within clinical trials to slow down decline of kidney function… read more here.
Keywords: min 73m2; 73m2 per; tolvaptan; treatment ... See more keywords
A5860 Risk factors for hypernatremia in patients with short- and long-term tolvaptan treatment.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Hypertension"
DOI: 10.1097/01.hjh.0000548697.58175.00
Abstract: Objectives: The long-term efficacy of tolvaptan, a vasopressin V2 receptor antagonist, has been reported. However, the safety of long-term treatment remains to be fully elucidated. We assessed the safety profile of tolvaptan with respect to… read more here.
Keywords: term; tolvaptan; long term; treatment ... See more keywords
Short-Term Efficacy and Safety of Tolvaptan in Patients with Left Ventricular Assist Devices
Sign Up to like & getrecommendations! Published in 2019 at "ASAIO Journal"
DOI: 10.1097/mat.0000000000001079
Abstract: Supplemental Digital Content is available in the text. Tolvaptan is an effective therapy for heart failure patients with symptomatic congestion and hyponatremia. The efficacy of its use in patients with continuous-flow left ventricular assist devices… read more here.
Keywords: therapy; tolvaptan; efficacy; ventricular assist ... See more keywords
Evaluating Impact of Implementing Order Questions on Appropriate Prescribing of Tolvaptan.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of pharmacy practice"
DOI: 10.1177/08971900221087079
Abstract: BACKGROUND Tolvaptan poses a significant risk to patient safety due to its risk of overcorrection of hyponatremia, and its cost-effectiveness is not well established. Kettering Health implemented order questions into Epic in 2019 to drive… read more here.
Keywords: tolvaptan; order; order questions; appropriate use ... See more keywords
Potential effect of tolvaptan on polycystic liver disease for patients with ADPKD meeting the Japanese criteria of tolvaptan use
Sign Up to like & getrecommendations! Published in 2022 at "PLoS ONE"
DOI: 10.1371/journal.pone.0264065
Abstract: Polycystic liver disease (PLD) is a common extrarenal complication of autosomal dominant polycystic kidney disease (ADPKD), which causes compression-related syndrome and ultimately leads to liver dysfunction. Tolvaptan, a V2 receptor antagonist, is widely used to… read more here.
Keywords: liver; effect; tolvaptan; tolvaptan group ... See more keywords